Overview

• A multinational analysis of 1,804 patients from three major trials found patient-reported physical function strongly predicts survival and treatment response to daratumumab in multiple myeloma.
• Patients with low baseline physical function saw a 47% reduction in mortality risk and a 66% lower risk of disease progression when treated with daratumumab compared to standard regimens.
• In contrast, patients with higher physical function showed less pronounced benefits, with only a 14% reduction in mortality risk and a 47% reduction in progression risk.
• The commonly used ECOG Performance Status, a clinician-assessed tool, failed to reliably identify patients who would benefit most, underscoring the need for patient-reported measures.
• Experts are urging the integration of patient-reported outcomes into routine oncology workflows to enhance personalized treatment strategies, particularly for older or frail populations.